Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: how useful are prognostic indices in routine clinical practice?

摘要: Although different prognostic indices for malignant gliomas have been developed, their validity outside of clinical trials has not widely tested. The aim this study was to determine whether the Medical Research Council (MRC) brain tumour index able stratify patients survival managed in routine practice, and secondly compare results with our newly developed score which included grade only 3 groups. MRC new were calculated a group 119 adult glioma by surgical resection/biopsy post-operative radiotherapy. For score, 6 groups defined, respectively. all median 11 (2-66) months. overall rate at 12 24 months 43% 18%, two-year rates 14 26% 1-10, 27% 11-15, 13 22% 16-20, 8 10% 21-25, 0% those scoring 26-33. There one patient 34-38 group. index, respectively 16 26%; 23%; 7% good, intermediate poor Both significant factors univariate analysis (MRC p = 0.0089, 0.0002), but multivariate analysis. devised separate into good groups, may aid treatment decisions, although there less differentiation between especially over first year. scores use routinely available factors. However, inclusion be an advantage index.